On August 3, Baxter rose 5.35% in regular trading, trading at $27.59/share, with turnover of approximately $20.91 million.
The rally was driven by the company's Q2 earnings report released on July 30, which significantly exceeded market expectations. Adjusted EPS came in at $0.54, beating the consensus estimate of $0.37 by approximately 46%. Revenue of $2.96 billion also topped expectations of $2.80 billion. Additionally, Baxter raised its full-year adjusted EPS guidance to $1.95-$2.15, above the prior range of $1.85-$2.05 and the FactSet estimate of $1.92.
Multiple institutions subsequently upgraded their views. Citigroup upgraded Baxter from Sell to Neutral on July 31, raising its price target from $17 to $28. Stifel also lifted its target from $19 to $24 while maintaining a Hold rating. The combination of strong operational results and concentrated analyst upgrades continued to fuel upward momentum in the stock.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments